Quaker Chemical (KWR) beats second-quarter earnings and revenue estimates

QUaker Chemical (KWR) posted quarterly earnings of $1.32 per share, beating Zacks’ consensus estimate of $1.08 per share. That compares to earnings of $1.82 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 22.22%. A quarter ago, this specialty chemicals company was expected to post a profit of $1.42 per share when it actually produced a profit of $1.42, unsurprisingly.

In the past four quarters, the company has exceeded consensus EPS estimates twice.

chemical quaker, which is industry-owned Zacks Chemical – Specialty, reported revenue of $492.39 million for the quarter ended June 2022, beating Zacks’ consensus estimate of 5.66%. That compares to revenues of $435.26 million a year ago. The company has exceeded consensus revenue estimates twice in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.

Shares of Quaker Chemical have lost about 32.8% year-to-date compared to a -12.8% decline for the S&P 500.

What’s next for Quaker Chemical?

As Quaker Chemical has underperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?

There is no easy answer to this key question, but a reliable measure that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Prior to this publication of results, the trend of revisions to estimates for Quaker Chemical: unfavourable. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation translates into a Zacks No. 5 ranking (strong sell) for the stock. Thus, stocks are expected to underperform the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.80 on $500.94 million in revenue for the upcoming quarter and $6.08 on $1.92 billion in revenue for the current fiscal year.

Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, Chemical – Specialty is currently in the bottom 44% of over 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

Another stock in the same sector, Zymergen (ZY), has yet to report results for the quarter ending June 2022.

This bio-based product developer is expected to post a quarterly loss of $0.75 per share in its next report, representing a year-over-year change of +42.3%. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.

Zymergen revenue is expected to be $3.25 million, down 44.9% from the prior year quarter.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 preferred stock to earn +100% or more in 2021. Previous recommendations have skyrocketed +143.0%, +175.9%, + 498.3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

Quaker Houghton (KWR): Free Stock Analysis Report

Zymergen Inc. (ZY): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.